PURPOSE: To determine the maximum tolerated dose (MTD) in a phase I trial on adaptive dose-painting-by-numbers (DPBN) for non-metastatic head and neck cancer. MATERIALS AND METHODS: Adaptive intensity-modulated radiotherapy was based on voxel intensity of pre-treatment and per-treatment [(18)F]fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG-PET) scans. Dose was escalated to a median total dose of 80.9 Gy in the high-dose clinical target volume (dose level I) and 85.9 Gy in the gross tumor volume (dose level II). The MTD would be reached, if ≥ 33% of patients developed any grade ≥ 4 toxicity (DLT) up to 3 months follow-up. RESULTS: Between February 2007 and August 2009, seven patients at dose level I and 14 at dose level II were treated. All patients completed treatment without interruption. At a median follow-up for surviving patients of 38 (dose level I) and 22 months (dose level II) there was no grade ≥ 4 toxicity during treatment and follow-up but six cases of mucosal ulcers at latency of 4-10 months, of which five (36%) were observed at dose level II. Mucosal ulcers healed spontaneously in four patients. CONCLUSIONS: Considering late mucosal ulcers as DLT, the MTD of a median dose of 80.9 Gy has been reached in our trial.
PURPOSE: To determine the maximum tolerated dose (MTD) in a phase I trial on adaptive dose-painting-by-numbers (DPBN) for non-metastatic head and neck cancer. MATERIALS AND METHODS: Adaptive intensity-modulated radiotherapy was based on voxel intensity of pre-treatment and per-treatment [(18)F]fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG-PET) scans. Dose was escalated to a median total dose of 80.9 Gy in the high-dose clinical target volume (dose level I) and 85.9 Gy in the gross tumor volume (dose level II). The MTD would be reached, if ≥ 33% of patients developed any grade ≥ 4 toxicity (DLT) up to 3 months follow-up. RESULTS: Between February 2007 and August 2009, seven patients at dose level I and 14 at dose level II were treated. All patients completed treatment without interruption. At a median follow-up for surviving patients of 38 (dose level I) and 22 months (dose level II) there was no grade ≥ 4 toxicity during treatment and follow-up but six cases of mucosal ulcers at latency of 4-10 months, of which five (36%) were observed at dose level II. Mucosal ulcers healed spontaneously in four patients. CONCLUSIONS: Considering late mucosal ulcers as DLT, the MTD of a median dose of 80.9 Gy has been reached in our trial.
Authors: Abdallah S R Mohamed; Carlos E Cardenas; Adam S Garden; Musaddiq J Awan; Crosby D Rock; Sarah A Westergaard; G Brandon Gunn; Abdelaziz M Belal; Ahmed G El-Gowily; Stephen Y Lai; David I Rosenthal; Clifton D Fuller; Michalis Aristophanous Journal: Radiother Oncol Date: 2017-07-31 Impact factor: 6.280
Authors: J H Rasmussen; B M Fischer; M C Aznar; A E Hansen; I R Vogelius; J Löfgren; F L Andersen; A Loft; A Kjaer; L Højgaard; L Specht Journal: Br J Radiol Date: 2015-01-30 Impact factor: 3.039
Authors: Julie Schatteman; Dirk Van Gestel; Dieter Berwouts; Werner De Gersem; Geert De Kerf; Wilfried De Neve; Bie De Ost; Ana Maria Luiza Olteanu; Sylvie Rottey; Tom Vercauteren; Ingeborg Goethals; Fréderic Duprez Journal: Strahlenther Onkol Date: 2018-03-19 Impact factor: 3.621
Authors: Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-26 Impact factor: 9.236
Authors: Anne K Due; Ivan R Vogelius; Marianne C Aznar; Søren M Bentzen; Anne K Berthelsen; Stine S Korreman; Annika Loft; Claus A Kristensen; Lena Specht Journal: Radiother Oncol Date: 2014-06-30 Impact factor: 6.280